Medication info
Polminlina Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Polminlina Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Green Cross Corp.
Appearance
White oval sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400695 · Approved 2024.03.29 · Insurance code 643606680

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredient. If a patient repeatedly reports finding this medicine in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General precautions). Take 1 tablet of this medicine 5/1000 mg extended-release once daily. Patients taking this medicine 2.5/1000 mg extended-release should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and dosage adjustments made as appropriate, if needed. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Green Cross Corp.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist patients with type 2 diabetes who need to take Linagliptin and Metformin together in controlling their blood sugar levels. It helps manage blood sugar effectively in conjunction with diet and exercise therapy. This assists in improving the health of patients who struggle with blood sugar control.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredient. If a patient repeatedly reports finding this medicine in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General precautions). Take 1 tablet of this medicine 5/1000 mg extended-release once daily. Patients taking this medicine 2.5/1000 mg extended-release should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and dosage adjustments made as appropriate, if needed. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication assists in controlling blood sugar levels. However, it may rarely cause a serious condition known as lactic acidosis, so caution is advised. It should not be used in individuals with allergies to its components or those with type 1 diabetes, severe renal impairment, acute cardiac conditions, liver dysfunction, etc. Also, it should be avoided in the presence of acute diseases such as dehydration, severe infections, or shock. Care must be taken for hypoglycemic symptoms when using this medication, especially when taken with other hypoglycemic agents. Patients with reduced renal function should undergo regular kidney function tests, and medication dosage adjustments may be necessary depending on their condition. Acute pancreatitis or blistering skin diseases may occur; therefore, if severe abdominal pain or skin abnormalities occur during treatment, inform a healthcare provider immediately. This medication should be swallowed whole and must not be broken, crushed, or chewed; the tablet coating may pass in the stool, which is normal. It is advisable to avoid using this medication during pregnancy or breastfeeding. Elderly patients should use this medication with increased caution due to a higher risk of renal impairment, with regular kidney function tests required. Additionally, this medication may pose risks when taken with alcohol, so it is better to avoid drinking. While receiving this medication, blood sugar levels and health status should be closely monitored, and if any abnormal symptoms appear, a healthcare provider should be consulted immediately.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disorders, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, papular dermatitis, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reactions, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, reduced appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorders, insomnia, depression, contusions, bone contusions, concussion, bone fractures, hand fractures, unstable angina, palpitations, dry eye, glaucoma, cataract, eye discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, fatty liver disease, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, dizziness, sensory loss, chest discomfort, asthenia, pain, nosebleeds, oropharyngeal pain, voice disorders, allergic rhinitis, exertional dyspnea, productive cough, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urinary albumin/creatinine ratio, positive urinary leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male pattern baldness, hyperhidrosis, dermatitis, anxiety, delirium, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to store it at room temperature, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White oval sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.